US House Restricts EPA's Scientific Advisory Board

The US House of Representatives, now with a Republican party majority, is seeking to make good on its pledge to declaw the Environmental Protection Agency, EPA. Earlier this week the House passed a bill that would change the rules for appointing members to the Science Advisory Board (SAB), which provides scientific advice to the agency.

Among many other things, the bill bans the advisory board's members from participating in activities that directly or indirectly involve review or evaluation of their own work. A scientist who has published a peer-reviewed paper on a particular topic, for example, would not be able to advise the EPA on the findings contained within that paper.

The administration of US President Barack Obama said it would veto the bill, which it said would negatively affect the appointment of experts and would weaken the scientific independence and integrity of the SAB.

Andrew A. Rosenberg, director of the Union of Concerned Scientists, wrote a letter to House Representatives saying the bill "effectively turns the idea of conflict of interest on its head, with the bizarre presumption that corporate experts with direct financial interests are not conflicted while academics who work on these issues are."

An evaluation by a scientist with expertise on topics the Science Advisory Board addresses likely will have done peer-reviewed studies on that topic, making the opinion more valuable, not less, Rosenberg added.

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.